Toalson Patrick, Ahmed Saeeduddin, Hardy Thomas, Kabinoff Gary
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind., and Jupiter Medical Center, Jupiter, Fla., and Martin Memorial Medical Center, Stuart, Fla.
Prim Care Companion J Clin Psychiatry. 2004;6(4):152-158. doi: 10.4088/pcc.v06n0402.
Since the introduction of the first atypical antipsychotics in the early 1990s, this class of medication has been increasingly relied upon for the treatment of a variety of patients with psychotic and mood disorders.DATA SOURCES: The following retrospective review was derived from the MEDLINE database using the search terms metabolic syndrome, insulin resistance, obesity, diabetes, severe mental illness, schizophrenia, bipolar disorder, mood disorders, depression, unipolar depression, and prevalence from 1966 to the present. LITERATURE SYNTHESIS: Coincident with the growing usage of these agents, there have been a growing number of literature reports of changes in metabolic homeostasis among patients taking these medications. These changes have led to interest in evaluating whether there is a relationship among these mental illnesses, their psychiatric treatments, and certain physical comorbidities known collectively as the metabolic syndrome. This article reviews the existing literature around the metabolic syndrome in patients with severe mental illnesses. CONCLUSION: Patients with severe mental illnesses, particularly schizophrenia and chronic mood disorders, demonstrate a higher prevalence of metabolic syndrome or its components compared with the general population. Based upon this increased risk in these patients, baseline and periodic medical evaluations should become a standard component in ongoing clinical assessment.
自20世纪90年代初首次引入非典型抗精神病药物以来,这类药物越来越多地被用于治疗各种患有精神疾病和情绪障碍的患者。
以下回顾性综述源自MEDLINE数据库,使用了从1966年至今的搜索词代谢综合征、胰岛素抵抗、肥胖症、糖尿病、严重精神疾病、精神分裂症、双相情感障碍、情绪障碍、抑郁症、单相抑郁症和患病率。
随着这些药物使用的增加,越来越多的文献报道了服用这些药物的患者代谢稳态的变化。这些变化引发了人们对评估这些精神疾病、其精神治疗方法与某些统称为代谢综合征的身体合并症之间是否存在关联的兴趣。本文综述了有关严重精神疾病患者代谢综合征的现有文献。
与普通人群相比,严重精神疾病患者,尤其是精神分裂症和慢性情绪障碍患者,代谢综合征及其组成部分的患病率更高。基于这些患者风险的增加,基线和定期医学评估应成为持续临床评估的标准组成部分。